- Home
- IONS vs RYTM Comparison
IONS vs RYTM Comparison
Compare IONS & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- RYTM
- Stock Information
- Founded
- IONS 1989
- RYTM 2008
- Country
- IONS United States
- RYTM United States
- Employees
- IONS N/A
- RYTM N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- IONS Health Care
- RYTM Health Care
- Exchange
- IONS Nasdaq
- RYTM Nasdaq
- Market Cap
- IONS 4.6B
- RYTM 3.8B
- IPO Year
- IONS 1991
- RYTM 2017
- Fundamental
- Price
- IONS $28.40
- RYTM $61.74
- Analyst Decision
- IONS Buy
- RYTM Strong Buy
- Analyst Count
- IONS 18
- RYTM 12
- Target Price
- IONS $57.00
- RYTM $74.92
- AVG Volume (30 Days)
- IONS 2.0M
- RYTM 940.6K
- Earning Date
- IONS 04-30-2025
- RYTM 05-06-2025
- Dividend Yield
- IONS N/A
- RYTM N/A
- EPS Growth
- IONS N/A
- RYTM N/A
- EPS
- IONS N/A
- RYTM N/A
- Revenue
- IONS $705,138,000.00
- RYTM $130,126,000.00
- Revenue This Year
- IONS N/A
- RYTM $43.84
- Revenue Next Year
- IONS $25.80
- RYTM $65.62
- P/E Ratio
- IONS N/A
- RYTM N/A
- Revenue Growth
- IONS N/A
- RYTM 68.06
- 52 Week Low
- IONS $23.95
- RYTM $35.17
- 52 Week High
- IONS $52.34
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- IONS 44.54
- RYTM 61.94
- Support Level
- IONS $27.57
- RYTM $59.54
- Resistance Level
- IONS $29.04
- RYTM $62.83
- Average True Range (ATR)
- IONS 1.79
- RYTM 4.27
- MACD
- IONS 0.12
- RYTM 1.00
- Stochastic Oscillator
- IONS 68.15
- RYTM 92.04
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.